IFNA2 and COVID-19: Moreover, while anti-IFNα/β antibodies that prevent IFNα/β-induced inflammation have been described in patients with autoimmune polyendocrinopathy syndrome, SLE and COVID-19 (25, 50, 51), it is unclear whether they are produced by patients with SCD and whether they contribute to the variable disease progression during viral infection.